1
|
Passannante R, Gómez-Vallejo V, Sagartzazu-Aizpurua M, Vignau Arsuaga L, Marco-Moreno P, Aldanondo G, Vallejo-Illarramendi A, Aguiar P, Cossío U, Martín A, Bergare J, Kingston L, Elmore CS, Morcillo MA, Ferrón P, Aizpurua JM, Llop J. Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders. Biomedicines 2023; 11:biomedicines11020253. [PMID: 36830793 PMCID: PMC9953224 DOI: 10.3390/biomedicines11020253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 01/12/2023] [Accepted: 01/13/2023] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The determination of pharmacokinetic properties of new chemical entities is a key step in the process of drug development. Positron emission tomography (PET) is an ideal technique to obtain both biodistribution and pharmacokinetic parameters of new compounds over a wide range of chemical modalities. Here, we use a multi-radionuclide/multi-position labelling approach to investigate distribution, elimination, and metabolism of a triazole-based FKBP12 ligand (AHK2) with potential application in neuromuscular disorders. METHODS Target engagement and stabilizing capacity of the drug candidate (AHK2) towards FKBP12-RyR was evaluated using competitive ligand binding and proximity ligation assays, respectively. Subsequently, AHK2 was labelled either with the positron emitter carbon-11 (11C) via 11C-methylation to yield both [11C]AHK2.1 and [11C]AHK2.2, or by palladium-catalysed reduction of the corresponding 5-iodotriazole derivative using 3H gas to yield [3H]AHK2. Metabolism was first investigated in vitro using liver microsomes. PET imaging studies in rats after intravenous (IV) administration at different doses (1 µg/Kg and 5 mg/Kg) were combined with determination of arterial blood time-activity curves (TACs) and analysis of plasma samples by high performance liquid chromatography (HPLC) to quantify radioactive metabolites. Arterial TACs were obtained in continuous mode by using an in-house developed system that enables extracorporeal blood circulation and continuous measurement of radioactivity in the blood. Pharmacokinetic parameters were determined by non-compartmental modelling of the TACs. RESULTS In vitro studies indicate that AHK2 binds to FKBP12 at the rapamycin-binding pocket, presenting activity as a FKBP12/RyR stabilizer. [11C]AHK2.1, [11C]AHK2.2 and [3H]AHK2 could be obtained in overall non-decay corrected radiochemical yields of 14 ± 2%, 15 ± 2% and 0.05%, respectively. Molar activities were 60-110 GBq/µmol, 68-122 GBq/µmol and 0.4-0.5 GBq/μmol, respectively. In vitro results showed that oxidation of the thioether group into sulfoxide, demethylation of the CH3O-Ar residue and demethylation of -N(CH3)2 were the main metabolic pathways. Fast metabolism was observed in vivo. Pharmacokinetic parameters obtained from metabolite-corrected arterial blood TACs showed a short half-life (12.6 ± 3.3 min). Dynamic PET imaging showed elimination via urine when [11C]AHK2.2 was administered, probably reflecting the biodistribution of [11C]methanol as the major metabolite. Contrarily, accumulation in the gastrointestinal track was observed after administration of [11C]AKH2.1. CONCLUSIONS AHK2 binds to FKBP12 at the rapamycin-binding pocket, presenting activity as a FKBP12/RyR stabilizer. Studies performed with the 3H- and 11C-labelled FKBP12/RyR stabilizer AHK2 confirm fast blood clearance, linear pharmacokinetics and rapid metabolism involving oxidation of the sulfide and amine moieties and oxidative demethylation of the CH3-O-Ar and tertiary amine groups as the main pathways. PET studies suggest that knowledge about metabolic pathways is paramount to interpret images.
Collapse
Affiliation(s)
- Rossana Passannante
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastián, Spain
| | - Vanessa Gómez-Vallejo
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastián, Spain
| | | | - Laura Vignau Arsuaga
- Departamento de Química Orgánica-I, UPV/EHU-University of the Basque Country, 20018 San Sebastián, Spain
| | - Pablo Marco-Moreno
- Group of Neuromuscular Diseases, Biodonostia Health Research Institute, 20014 San Sebastián, Spain
| | - Garazi Aldanondo
- Group of Neuromuscular Diseases, Biodonostia Health Research Institute, 20014 San Sebastián, Spain
- Deusto Physical TherapIker, Physical Therapy Department, Faculty of Health Sciences, University of Deusto, 20012 San Sebastián, Spain
| | - Ainara Vallejo-Illarramendi
- Group of Neuromuscular Diseases, Biodonostia Health Research Institute, 20014 San Sebastián, Spain
- Group of Neuroscience, Department of Pediatrics, Hospital Donostia, UPV/EHU, 20014 San Sebastián, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, IDIS, CIMUS, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Unai Cossío
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastián, Spain
| | - Abraham Martín
- Ikerbasque, Basque Foundation for Science, Maria Diaz de Haro 3, 48013 Bilbao, Spain
- Laboratory of Neuroimaging and Biomarkers of Inflammation, Achucarro Basque Center for Neuroscience, Science Park UPV/EHU, Sede Building B, Sarriena, 48940 Leioa, Spain
| | - Jonas Bergare
- Early Chemical Development, Pharmaceutical Sciences R&D, AstraZeneca, 431 83 Gothenburg, Sweden
| | - Lee Kingston
- Early Chemical Development, Pharmaceutical Sciences R&D, AstraZeneca, 431 83 Gothenburg, Sweden
| | - Charles S. Elmore
- Early Chemical Development, Pharmaceutical Sciences R&D, AstraZeneca, 431 83 Gothenburg, Sweden
| | | | - Pablo Ferrón
- Miramoon Pharma S.L., Avda Tolosa-72, 20018 San Sebastián, Spain
| | - Jesus M. Aizpurua
- Departamento de Química Orgánica-I, UPV/EHU-University of the Basque Country, 20018 San Sebastián, Spain
| | - Jordi Llop
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), 20014 San Sebastián, Spain
- Correspondence:
| |
Collapse
|
2
|
Aizpurua JM, Miranda JI, Irastorza A, Torres E, Eceiza M, Sagartzazu-Aizpurua M, Ferrón P, Aldanondo G, Lasa-Fernández H, Marco-Moreno P, Dadie N, López de Munain A, Vallejo-Illarramendi A. Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress. Eur J Med Chem 2021; 213:113160. [PMID: 33493827 DOI: 10.1016/j.ejmech.2021.113160] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 12/23/2020] [Accepted: 01/04/2021] [Indexed: 10/22/2022]
Abstract
The hypothesis of rescuing FKBP12/RyR1 interaction and intracellular calcium homeostasis through molecular "reshaping" of FKBP12 was investigated. To this end, novel 4-arylthioalkyl-1-carboxyalkyl-1,2,3-triazoles were designed and synthesized, and their efficacy was tested in human myotubes. A library of 17 compounds (10a-n) designed to dock the FKBP12/RyR1 hot-spot interface contact residues, was readily prepared from free α-amino acids and arylthioalkynes using CuAAC "click" protocols amenable to one-pot transformations in high overall yields and total configurational integrity. To model nitro-oxidative stress, human myotubes were treated with the peroxynitrite donor SIN1, and evidence was found that some triazoles 10 were able to normalize calcium levels, as well as FKBP12/RyR1 interaction. For example, compound 10 b at 150 nM rescued 46% of FKBP12/RyR1 interaction and up to 70% of resting cytosolic calcium levels in human myotubes under nitro-oxidative stress. All compounds 10 analyzed showed target engagement to FKBP12 and low levels of cytotoxicity in vitro. Compounds 10b, 10c, 10h, and 10iR were identified as potential therapeutic candidates to protect myotubes in muscle disorders with underlying nitro-oxidative stress, FKBP12/RyR1 dysfunction and calcium dysregulation.
Collapse
Affiliation(s)
- Jesus M Aizpurua
- Joxe Mari Korta R&D Center, Departamento de Química Orgánica-I, Universidad Del País Vasco UPV/EHU, Avda. Tolosa-72, 20018, San Sebastián, Spain.
| | - José I Miranda
- Joxe Mari Korta R&D Center, Departamento de Química Orgánica-I, Universidad Del País Vasco UPV/EHU, Avda. Tolosa-72, 20018, San Sebastián, Spain
| | - Aitziber Irastorza
- Joxe Mari Korta R&D Center, Departamento de Química Orgánica-I, Universidad Del País Vasco UPV/EHU, Avda. Tolosa-72, 20018, San Sebastián, Spain
| | - Endika Torres
- Joxe Mari Korta R&D Center, Departamento de Química Orgánica-I, Universidad Del País Vasco UPV/EHU, Avda. Tolosa-72, 20018, San Sebastián, Spain
| | - Maite Eceiza
- Joxe Mari Korta R&D Center, Departamento de Química Orgánica-I, Universidad Del País Vasco UPV/EHU, Avda. Tolosa-72, 20018, San Sebastián, Spain
| | - Maialen Sagartzazu-Aizpurua
- Joxe Mari Korta R&D Center, Departamento de Química Orgánica-I, Universidad Del País Vasco UPV/EHU, Avda. Tolosa-72, 20018, San Sebastián, Spain
| | - Pablo Ferrón
- Miramoon Pharma S.L., Avda Tolosa-72, 20018, San Sebastián, Spain
| | - Garazi Aldanondo
- Instituto de Investigación Sanitaria Biodonostia, Grupo de Enfermedades Neuromusculares, Paseo Dr Begiristain s/n, 20014, San Sebastián, Spain; CIBERNED, Instituto de Salud Carlos III, 28031, Madrid, Spain
| | - Haizpea Lasa-Fernández
- Instituto de Investigación Sanitaria Biodonostia, Grupo de Enfermedades Neuromusculares, Paseo Dr Begiristain s/n, 20014, San Sebastián, Spain; CIBERNED, Instituto de Salud Carlos III, 28031, Madrid, Spain; Grupo de Neurosciencias, Departamentos de Pediatría y Neurociencias, Universidad Del País Vasco UPV/EHU, Hospital Donostia, Paseo Dr Begiristain S/n, 20014, San Sebastián, Spain
| | - Pablo Marco-Moreno
- Instituto de Investigación Sanitaria Biodonostia, Grupo de Enfermedades Neuromusculares, Paseo Dr Begiristain s/n, 20014, San Sebastián, Spain; CIBERNED, Instituto de Salud Carlos III, 28031, Madrid, Spain
| | - Naroa Dadie
- Grupo de Neurosciencias, Departamentos de Pediatría y Neurociencias, Universidad Del País Vasco UPV/EHU, Hospital Donostia, Paseo Dr Begiristain S/n, 20014, San Sebastián, Spain
| | - Adolfo López de Munain
- Instituto de Investigación Sanitaria Biodonostia, Grupo de Enfermedades Neuromusculares, Paseo Dr Begiristain s/n, 20014, San Sebastián, Spain; CIBERNED, Instituto de Salud Carlos III, 28031, Madrid, Spain; Grupo de Neurosciencias, Departamentos de Pediatría y Neurociencias, Universidad Del País Vasco UPV/EHU, Hospital Donostia, Paseo Dr Begiristain S/n, 20014, San Sebastián, Spain
| | - Ainara Vallejo-Illarramendi
- Instituto de Investigación Sanitaria Biodonostia, Grupo de Enfermedades Neuromusculares, Paseo Dr Begiristain s/n, 20014, San Sebastián, Spain; CIBERNED, Instituto de Salud Carlos III, 28031, Madrid, Spain; Grupo de Neurosciencias, Departamentos de Pediatría y Neurociencias, Universidad Del País Vasco UPV/EHU, Hospital Donostia, Paseo Dr Begiristain S/n, 20014, San Sebastián, Spain.
| |
Collapse
|